Study guide

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols

Key Takeaways Explain This Topic AI

Phase-specific agents are schedule-dependent (vincristine at M-phase, antimetabolites at S-phase, etoposide at G2/S); alkylators and platinum agents are cell-cycle nonspecific.

Vincristine given intrathecally is fatal: independently double-check route, never prepare it in a syringe at the same time as intrathecal methotrexate, and keep it off the lumbar-puncture field.

High-dose methotrexate requires hydration, urine alkalinization, leucovorin rescue, and level monitoring; mercaptopurine involves TPMT; high-dose cytarabine needs steroid eye drops; nelarabine is neurotoxic.

Signature class toxicities include anthracycline cardiomyopathy and lifetime cumulative dose, alkylator hemorrhagic cystitis (mesna plus hydration) and ifosfamide encephalopathy, platinum ototoxicity and delayed nausea, and asparaginase hypersensitivity, thrombosis, pancreatitis, and hyperglycemia.

Pediatric protocols are multi-agent, risk-adapted, and include CNS prophylaxis; most older children are dosed by BSA (mg/m²) and many infants by weight (mg/kg)—do not treat one cooperative-group protocol number as the 2026 national standard.

Last updated: August 2026

Chemotherapy remains the backbone of most pediatric cancer protocols. CPHON Domain III.A.1 and III.B.1 cluster hematologic and solid-tumor chemotherapy together: you are tested on cell-cycle logic, class-specific toxicities, and how pediatric protocols actually run—not on reciting a single cooperative-group protocol number as the 2026 standard.

Pediatric regimens are multi-agent , risk-adapted , and almost always include central nervous system (CNS) prophylaxis when the disease can hide in sanctuary sites. Doses are calculated from body surface area (BSA) in most school-age children and from weight in many infant pathways. Independent double-checks exist because one wrong route—especially intrathecal (IT) vincristine —kills.

Cell-cycle phase-specific versus nonspecific

Malignant cells move through G0 (rest), G1 (growth), S (DNA synthesis), G2 (prepare to divide), and M (mitosis). Phase-specific drugs kill cells in one window and are schedule-dependent: a delayed S-phase infusion is not the same treatment as the dose given on time. Phase-nonspecific drugs damage DNA whether the cell is dividing or resting; they are more dose-dependent. Multi-agent pediatric backbones combine both so clones in different phases are hit and so toxicities do not all land on the same organ on the same day.

  • Class Cycle relationship Pediatric exemplars Signature toxicities
  • Vinca alkaloids M-phase specific vincristine Neuropathy, constipation, rare SIADH; fatal if given IT

Antimetabolites S-phase specific methotrexate, mercaptopurine, cytarabine, nelarabine MTX mucositis/nephrotoxicity with leucovorin rescue; 6-MP hepatotoxicity/TPMT; HD cytarabine conjunctivitis; nelarabine neurotoxicity

Epipodophyllotoxins G2/S etoposide Infusion hypotension; secondary AML risk concept

Anthracyclines Often classified nonspecific doxorubicin, daunorubicin Cardiomyopathy, red-orange urine, vesicant; lifetime cumulative dose; dexrazoxane on some protocols

Alkylators Nonspecific cyclophosphamide, ifosfamide Hemorrhagic cystitis (mesna + hydration); ifosfamide encephalopathy

Platinum Nonspecific cisplatin, carboplatin Ototoxicity, nephrotoxicity, delayed CINV

Asparaginase products Enzyme depletion asparaginase, pegaspargase Hypersensitivity, thrombosis, pancreatitis, hyperglycemia

Corticosteroids Lympholytic prednisone, dexamethasone Mood, gastritis, avascular necrosis, infection

A 5-year-old on ALL induction is living this table in one week: dexamethasone (mood, gastritis), vincristine (constipation, neuropathy, vesicant, IV only), pegaspargase (pancreas, clot, allergy), and often an anthracycline (heart, vesicant, red urine). The nurse who studies classes as a list but cannot attach a bedside watch will miss the exam item.

Vinca alkaloids — the IT never event

Vincristine is the pediatric workhorse vinca. It causes peripheral neuropathy (foot drop, jaw pain, loss of deep-tendon reflexes), ileus and constipation that can progress to obstruction, and rarely the syndrome of inappropriate antidiuretic hormone secretion (SIADH) . It is a vesicant .

The item that must never be missed: vincristine given intrathecally is fatal . Accidental IT vincristine has killed children. Nursing controls are not optional etiquette:

Two-nurse independent verification of route as well as patient, drug, and dose.

Never prepare or have vincristine in a syringe at the same time as IT methotrexate is being drawn or carried to the lumbar-puncture tray.

Many institutions dispense intravenous vincristine in a minibag , not a syringe, so it cannot be injected into a spinal needle.

IT methotrexate is preservative-free and labeled for IT use; vincristine is never labeled for IT use.

If someone hands you "the IT syringe" and it is vincristine, you stop the procedure. There is no slow-injection recovery.

Antimetabolites

Methotrexate (MTX) is given intravenously (including high-dose), intrathecally, and orally. High-dose MTX is its own nursing protocol: vigorous hydration, urine alkalinization (keep urine pH at or above the protocol threshold, commonly around 7), timed leucovorin rescue , and serial MTX levels. Escalate or extend rescue per protocol if clearance is delayed. Nonsteroidal anti-inflammatory drugs, proton-pump inhibitors, and some penicillins can delay MTX clearance—flag them before the bag is hung. Mucositis and nephrotoxicity are the headline toxicities; hepatotoxicity also occurs.

Mercaptopurine (6-MP) is the daily oral ALL-maintenance agent. Hepatotoxicity and myelosuppression are expected. Thiopurine methyltransferase (TPMT) —and NUDT15 on many contemporary panels—variants increase toxicity; protocol dose reductions follow genotype or unexpected cytopenia. Teach families not to crush or share tablets carelessly.

Cytarabine , especially high-dose, causes chemical conjunctivitis . Start prophylactic steroid eye drops during and after the protocol window. Cerebellar toxicity (nystagmus, ataxia, dysarthria) is a stop-and-notify finding. Nelarabine appears on T-ALL pathways and is famous for neurotoxicity: somnolence, neuropathy, and rare severe ascending weakness. A new inability to walk after nelarabine is not "tired from the hospital."

Anthracyclines, alkylators, platinum, enzymes, steroids, and etoposide

Doxorubicin and daunorubicin are vesicants. Urine and body fluids may turn red-orange; teach that this is expected pigment, not hemorrhage. The organ that limits lifetime therapy is the heart: cumulative lifetime dose is tracked in doxorubicin-equivalents on the treatment summary. Dexrazoxane appears as a cardioprotectant on some pediatric protocols and, separately, as an anthracycline-extravasation antidote concept. Echo surveillance belongs in late-effects teaching.

Cyclophosphamide and ifosfamide generate acrolein, which inflames the bladder. Mesna plus hyperhydration protect against hemorrhagic cystitis . Ifosfamide additionally causes encephalopathy (chloroacetaldehyde) and renal tubular injury. Confusion, somnolence, or new gross hematuria after an ifosfamide day is not "just chemo fatigue."

Cisplatin and carboplatin damage cochlear hair cells and renal tubules. Cisplatin is the classic delayed-nausea, magnesium-wasting, high-frequency hearing-loss drug. Carboplatin is more myelosuppressive and still ototoxic in young children. Serial audiograms are not optional after platinum. Delayed chemotherapy-induced nausea and vomiting (CINV) after cisplatin can last days—antiemetic teaching does not stop when the bag is empty.

Asparaginase and pegaspargase deplete asparagine. Watch hypersensitivity (may require a switch to an Erwinia-derived asparaginase such as crisantaspase), silent inactivation, thrombosis including CNS events, pancreatitis , and hyperglycemia . Abdominal pain after pegaspargase is pancreatitis until lipase says otherwise.

Corticosteroids (prednisone, dexamethasone) cause mood lability, gastritis, hyperglycemia, immunosuppression including Pneumocystis risk on ALL pathways, and avascular necrosis . Dexamethasone has more CNS penetration and a harsher AVN and myopathy profile on many protocols.

Etoposide can drop blood pressure if infused too fast. Slow the rate; do not assume anaphylaxis as the only cause of hypotension. Etoposide also carries a secondary AML risk concept, often KMT2A-rearranged and typically a few years later—teach the concept, not a made-up percentage.

Pediatric protocols and BSA dosing

Children's Oncology Group (COG) and other cooperative-group studies share a design language: multi-agent blocks , risk adaptation from age, white-cell count, genetics, CNS status, and measurable residual disease, and CNS-directed therapy (IT chemotherapy plus high-dose systemic agents with CNS penetration, with radiation reserved for selected high-risk CNS disease). Do not memorize one protocol code as the national 2026 standard; arms change. You will be tested on backbone logic and class toxicities.

BSA dosing (mg/m²) is the default for most cytotoxics in children who are not infants. A commonly used formula is Mosteller: BSA (m²) equals the square root of (height in cm times weight in kg, divided by 3600). Recalculate when weight changes. Infants are often dosed by weight (mg/kg) because BSA-based milligram totals can overdose a small baby; the cutoff may be age, weight, or a BSA threshold and is protocol-specific . Never invent a single infant cutoff as ONCC fact. Two nurses independently recheck height, weight, BSA or kg dose, caps, and the final milligram amount before hanging the bag.

Worked picture: a 6-year-old, 120 cm and 22 kg, has BSA of about 0.86 m² (square root of 2640/3600). Vincristine 1.5 mg/m² is about 1.3 mg, still under typical single-dose caps on many protocols. A 4-month-old at 6 kg is not automatically dosed from an adult-style BSA calculator without the infant rule on that protocol.

The CPHON product is a nurse who can name the class, the organ it injures, the rescue that belongs with it (leucovorin, mesna, steroid drops, dexrazoxane on selected protocols), and the one route that must never be used for vincristine.

Loading diagram... Cell-cycle targets of common pediatric chemotherapy classes